Organovo Holdings, Inc. (ONVO)
(Delayed Data from NSDQ)
$11.69 USD
-1.11 (-1.35%)
Updated Mar 3, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank | Definition | Annualized Return |
---|---|---|
1 | Strong Buy | 24.41% |
2 | Buy | 17.88% |
3 | Hold | 9.48% |
4 | Sell | 5.03% |
5 | Strong Sell | 1.87% |
S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value Score | A |
---|---|
Growth Score | A |
Momentum Score | A |
VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
NA Value
NA Growth NA Momentum NA VGMThe Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Zacks News
Will Organovo Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Organovo.
ONVONegative Net Change
medical
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
by Zacks Equity Research
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
QLYSNegative Net Change CYBRPositive Net Change AVGRNegative Net Change ONVONegative Net Change ALXNNegative Net Change
computers medical
What Bargain Hunting? Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E for outsized gains.
QLYSNegative Net Change CYBRPositive Net Change AVGRNegative Net Change ALXNNegative Net Change ONVONegative Net Change
earnings
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ONVONegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Organovo (ONVO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -13.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ONVONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ONVONegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Options Traders Expect Huge Moves in Organovo (ONVO) Stock
by Zacks Equity Research
Organovo (ONVO) needs investors to pay close attention to the stock based on moves in the options market lately.
ONVONegative Net Change
medical
Organovo (ONVO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 14.29% and -10.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
ONVONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Will Organovo (ONVO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ONVONegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
New Strong Buy Stocks for December 14th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
ONVONegative Net Change OFIXPositive Net Change ITGRNegative Net Change ILMNNegative Net Change BRKRNegative Net Change
biotechs industrial-products medical
Organovo (ONVO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 37.50% and 4.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
ONVONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ONVONegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Organovo (ONVO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -40.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
ONVONegative Net Change
5 Top Performing Stocks of the Best ETF of May
by Sweta Killa
Inside the best performing stocks of the top ETF of May - ARKG.
NVTANegative Net Change FMINegative Net Change NSTGNegative Net Change ONVONegative Net Change
Can The Uptrend Continue for Organovo Holdings (ONVO)?
by Zacks Equity Research
Investors certainly have to be happy with Organovo Holdings, Inc. (ONVO) and its short term performance
ONVONegative Net Change
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys
by Zacks Equity Research
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys
AMSCNegative Net Change SSYSNegative Net Change BTXNo Net Change ONVONegative Net Change
Try Rising P/E Investing With 5 Top-Ranked Stocks
by Zacks Equity Research
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
AMSCNegative Net Change SSYSNegative Net Change BTXNo Net Change ONVONegative Net Change
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
by Zacks Equity Research
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
SSYSNegative Net Change BTXNo Net Change ONVONegative Net Change MGENNegative Net Change
Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks
by Zacks Equity Research
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
SSYSNegative Net Change BTXNo Net Change ONVONegative Net Change MGENNegative Net Change
Zacks.com featured highlights: Fortuna Silver Mines, Ritter Pharmaceuticals , Organovo Holdings, Western Digital and Willdan Group
by Zacks Equity Research
Zacks.com featured highlights: Fortuna Silver Mines, Ritter Pharmaceuticals , Organovo Holdings, Western Digital and Willdan Group
WDCNegative Net Change WLDNPositive Net Change ONVONegative Net Change
Take the Less-Trodden Path: Rising P/E for 5 Winning Stocks
by Zacks Equity Research
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.
WDCNegative Net Change WLDNPositive Net Change ONVONegative Net Change
The Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek
CDXSNegative Net Change EMKRNegative Net Change IVACPositive Net Change ONVONegative Net Change